Previous Page  4 / 23 Next Page
Information
Show Menu
Previous Page 4 / 23 Next Page
Page Background

Page 35

A n n u a l S u mm i t o n

Hepatology and Pancreatic

Diseases

November 12-13 , 2018

Par i s , France

Journal of Clinical Gastroenterology and Hepatology

ISSN: 2575-7733

Hepatology and Pancreatic Diseases 2018

N

on-alcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease which may progress to non-

alcoholic steatohepatitis (NASH). Currently there are no therapeutic strategies for such disease. Only lifestyle modification

through diet and exercise were proven to afford some benefit in patients with NAFLD. No pharmacologic agents have so far been

approved for the treatment of NAFLD or NASH. Therefore, most clinical efforts have been directed at treating the components

of metabolic syndrome, namely obesity, diabetes, hypertension and dyslipidemias. Other interventions are directed at specific

pathways potentially involved in the pathogenesis of NAFLD, such as insulin resistance, oxidative stress, pro-inflammatory

cytokines, apoptosis, bacterial overgrowth, and angiotensin pathway. This lecture aims to show the potential of Tocotrienols as a

promising therapeutic option for NAFLD. This is a Systematic Review of the effects of Tocotrienols on Non-Alcoholic Fatty Liver

Disease. (NAFLD). Tocotrienols may yet prove to be an effective treatment for Non-Alcoholic Fatty Liver Disease

genemapmd@yahoo.com

The Efficacy of Tocotrienols in the Treatment of

Non-alcoholic Steatohepatitis: A Systematic Review

Higinio T. Mappala

Jose Reyes Mem. Medical Center, Philippines

J Clin Gastroenterol Hepatol 2018, Volume:2

DOI: 10.21767/2575-7733-C3-009